IN2012DN02869A - - Google Patents

Download PDF

Info

Publication number
IN2012DN02869A
IN2012DN02869A IN2869DEN2012A IN2012DN02869A IN 2012DN02869 A IN2012DN02869 A IN 2012DN02869A IN 2869DEN2012 A IN2869DEN2012 A IN 2869DEN2012A IN 2012DN02869 A IN2012DN02869 A IN 2012DN02869A
Authority
IN
India
Prior art keywords
peptide
specifically
humanized antibodies
antibodies
methods
Prior art date
Application number
Other languages
English (en)
Inventor
Yaakov Naparstek
Shira Yair
Original Assignee
Protab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protab Ltd filed Critical Protab Ltd
Publication of IN2012DN02869A publication Critical patent/IN2012DN02869A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1289—Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IN2869DEN2012 2009-09-06 2010-09-06 IN2012DN02869A (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24021809P 2009-09-06 2009-09-06
PCT/IL2010/000731 WO2011027349A1 (en) 2009-09-06 2010-09-06 Humanized antibodies specific for hsp65-derived peptide-6 methods and uses thereof

Publications (1)

Publication Number Publication Date
IN2012DN02869A true IN2012DN02869A (enExample) 2015-07-24

Family

ID=43648941

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2869DEN2012 IN2012DN02869A (enExample) 2009-09-06 2010-09-06

Country Status (12)

Country Link
US (3) US8680241B2 (enExample)
EP (2) EP2475383A4 (enExample)
JP (1) JP5781514B2 (enExample)
KR (1) KR101831229B1 (enExample)
CN (1) CN102740877B (enExample)
AU (1) AU2010290844B2 (enExample)
BR (1) BR112012004983A2 (enExample)
CA (1) CA2772567A1 (enExample)
IN (1) IN2012DN02869A (enExample)
MX (1) MX2012002768A (enExample)
RU (1) RU2596925C2 (enExample)
WO (1) WO2011027349A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE048024T2 (hu) * 2006-08-10 2020-05-28 Roy C Levitt Anakinra bronchiolitis obliterans szindróma kezelésében való alkalmazásra
ES2857553T3 (es) * 2014-10-24 2021-09-29 Hoffmann La Roche Humanización de anticuerpos basada en ángulo interdominio VH-VL
US10538561B2 (en) 2015-01-22 2020-01-21 Isanaka Ram Peptide for treating inflammatory diseases
US11623950B2 (en) * 2015-07-09 2023-04-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) Lentiviral vector expressing membrane-anchored or secreted antibody
MX385370B (es) * 2016-03-31 2025-03-18 Immutrix Therapeutics Inc Metodo para el tratamiento extracorporeo de preeclampsia y trastornos relacionados.
MX2021001268A (es) 2018-08-01 2021-09-08 Imcheck Therapeutics Sas Anticuerpos anti-btn3a y su uso en el tratamiento del cáncer o trastornos infecciosos.
WO2025155809A2 (en) * 2024-01-18 2025-07-24 Nextcure, Inc. Compositions and methods for modulating vstm-1 mediated signal transduction
WO2025231127A1 (en) * 2024-05-02 2025-11-06 The Regents Of The University Of California Compositions and methods for intracellular antigen targeting with antibodies

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9125979D0 (en) * 1991-12-06 1992-02-05 Wellcome Found Antibody
US7488476B2 (en) * 1998-11-05 2009-02-10 Hadasit Medical Research Services & Development Ltd. B-cell epitope peptides of HSP 65, DNA encoding said peptides, antibodies directed against said peptides and the different uses thereof in the treatment of inflammatory and autoimmune diseases
AU759303B2 (en) * 1998-11-05 2003-04-10 Hadasit Medical Research Services & Development Company Ltd Novel amino acid sequences, DNA encoding the amino acid sequences, antibodies directed against such sequences and the different uses thereof
AU2002360857A1 (en) * 2001-12-31 2003-07-24 L.A.S. Trust, Ein 02/6105365 Recreational vehicle
EP1619521A1 (en) 2004-07-22 2006-01-25 IEE INTERNATIONAL ELECTRONICS & ENGINEERING S.A. Capacitive transmitter electrode
CU23504A1 (es) * 2004-09-24 2010-04-13 Ct Ingenieria Genetica Biotech Péptidos y derivados tipo apl de la hsp60 y composiciones farmacéuticas
AU2006210724A1 (en) 2005-02-03 2006-08-10 Antitope Limited Human antibodies and proteins
US20070048325A1 (en) * 2005-08-24 2007-03-01 Dennis Van Epps Combination therapies for inhibiting integrin-extracellular matrix interactions
PL1989544T3 (pl) 2006-03-02 2012-01-31 Antitope Ltd Testy na komórkach T
US20080019979A1 (en) * 2006-05-22 2008-01-24 Feng Wang-Johanning HERV-K Antigens, Antibodies, and Methods
JPWO2008114733A1 (ja) 2007-03-16 2010-07-01 協和発酵キリン株式会社 抗Ｃｌａｕｄｉｎ−４抗体
UA104132C2 (en) 2007-11-13 2014-01-10 Тева Биофармасьютикалз Юесей, Инк. Humanized antibodies against tl1a
EP2414397A1 (en) 2009-03-30 2012-02-08 Protab Ltd. Adenylyl cyclase-associated protein (cap1) and uses thereof as a target for immuno-modulation
US20140170157A1 (en) * 2011-06-15 2014-06-19 Glaxosmithkline Intellectual Property (No.2) Limited Method of selecting therapeutic indications

Also Published As

Publication number Publication date
EP2475383A4 (en) 2013-07-17
WO2011027349A1 (en) 2011-03-10
RU2596925C2 (ru) 2016-09-10
EP2475383A1 (en) 2012-07-18
KR20120060224A (ko) 2012-06-11
BR112012004983A2 (pt) 2021-02-23
CA2772567A1 (en) 2011-03-10
JP5781514B2 (ja) 2015-09-24
AU2010290844B2 (en) 2015-04-09
CN102740877B (zh) 2015-01-14
CN102740877A (zh) 2012-10-17
JP2013503852A (ja) 2013-02-04
AU2010290844A1 (en) 2012-03-15
EP3366308A1 (en) 2018-08-29
US8680241B2 (en) 2014-03-25
US20120156201A1 (en) 2012-06-21
MX2012002768A (es) 2012-06-28
KR101831229B1 (ko) 2018-02-22
RU2012106891A (ru) 2013-10-27
US20140170138A1 (en) 2014-06-19
US20170218056A1 (en) 2017-08-03

Similar Documents

Publication Publication Date Title
IN2012DN02869A (enExample)
NZ596540A (en) Humanized antibodies specific to the protofibrillar form of the beta-amyloid peptide
NZ601793A (en) Methods and compositions for diagnosis and treatment of cancer
WO2005103083A8 (en) Anti-cd38 human antibodies and uses therefor
NZ601583A (en) Novel rabbit antibody humanization methods and humanized rabbit antibodies
NZ601615A (en) Antibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use therefor
NZ593550A (en) ANTI-Siglec-15 ANTIBODY
GB201112429D0 (en) Antigen-binding proteins with increased FcRn binding
NZ599140A (en) Antibodies that specifically bind to the epha2 receptor
NZ597023A (en) Monoclonal antibodies that bind to hGM-CSF and medical compositions comprising same
MX2009012949A (es) Anticuerpos humanizados que enlazan a ab (1-42) globulomero y usos de los mismos.
UA111818C2 (uk) Антитіло проти csf-1r
MX2012000841A (es) Optimizacion de la produccion de anticuerpos.
MX2009004532A (es) Composiciones y metodos para unir esfingosina-1-fosfato.
MX2011008843A (es) Anticuerpos humanizados que se unen a cd19 y sus usos.
EA201490677A1 (ru) Связывающие антиген cd27l белки
NZ612312A (en) Her2 binding peptides labeled with aluminium-[18] fluoride complexed by nota
NZ607969A (en) Cd33 binding agents
MX2010004660A (es) NUEVOS ANTICUERPOS ESPECIFICOS DE LOS PEPTIDOS ß-AMILOIDES Y SUS USOS COMO AGENTES DE DIAGNOSTICO Y DROGAS.
EP3144323A3 (en) Anti-c4.4a antibodies and uses thereof
SG10201408073XA (en) Muteins of human lipocalin 2 (lcn2, hngal) with affinity for a given target
MX2011008759A (es) Medios y metodos para fabricar neurotoxina altamente pura.
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
TN2012000466A1 (en) Humanized anti cxcr4 antibodies for the treatment of cancer
EA201290360A1 (ru) Гуманизированные антитела против il-22ra человека